Infosys raised its revenue forecast for the fourth straight quarter, projecting 4.5-5% growth for the 2024-25 fiscal year.

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Sabio Holdings Inc. (TSXV: SBIO) (OTCQB: SABOF) (the "Company" or "Sabio"), a Los Angeles-based ad-tech company specializing in helping top 100 global brands reach, engage, and validate (R.E.V) ...

After the announcement of strong Q3 results for the current financial year by two Indian IT giants, Tata Consultancy Services ...

We recently published a list of 12 Best Safe Dividend Stocks for 2025. In this article, we are going to take a look at where ...

In the September 2024 quarter, the retailer had shut around 43-44 stores in the south including Kerala, Tamil Nadu, Andhra ...

A review of Canada's 2024 labor market shows slow job growth, stable but tough conditions for job seekers, and uncertain ...

2024 was a stellar year for banking giants in the United States. According to a report in the Financial Times, the seven ...

Infosys Q3 results are expected to see flat sequential revenue growth in constant currency (CC) terms, while net profit ...

Transocean's strong contract coverage and floater fleet justify a premium valuation, but the stock remains expensive. Click ...

Other Cleveland companies had a standout performance to end the year, most notably CBIZ Inc. The company made a number of ...

Trends such as premiumisation and rising digital adoption will benefit its consumer-facing businesses while investments in ...